Authors

Latest:

Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening Rates

Isabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.

Monzr M. Al Malki, MD

Monzr M. Al Malki, MD, is an associate professor in the Division of Leukemia and Hematopoietic Cell Transplantation, director of Unrelated Donor BMT Program, and director of Haploidentical Transplant Program at City of Hope.

Latest:

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Robert Albert Anders, MD, PhD

Latest:

Dr Anders on the Investigation of CCR4 Antagonists in Advanced Cancers

Robert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.

Jorge Cortes, MD, Georgia Cancer Center

Latest:

Future Management of Chronic Myeloid Leukemia

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Jacob E. Berchuck, MD

Latest:

Dr Berchuck on Next Steps for Evaluating a Novel Liquid Biopsy for PSMA in mCRPC

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

Rachel Jimenez, MD

Latest:

Dr Jimenez on the Radiation Treatment Paradigm in Breast Cancer

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Syed Kazmi, MD

Latest:

Dr. Kazmi on Key Treatment Considerations for Young-Onset CRC

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.

Amanda Przespolewski, DO

Latest:

Notable Advancements in Treatment for ALL

Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.

Yovanni Casablanca, MD

Latest:

Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical Cancer

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Tarun Wasil, MBBS, FACP

Latest:

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Stephen Strickland, MD, MSCI, Director, Leukemia Research for Sarah Cannon Research Institute

Latest:

Five Factors That Guide How I Treat Adults with Chronic Myeloid Leukemia in Chronic Phase

Andrei H. Iagaru, MD

Latest:

Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate Cancer

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Ignacio Blanco, MD, PhD

Latest:

The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

Monica Balzarotti, MD

Latest:

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Beau Webber, PhD

Beau Webber, PhD, is associate professor in the Division of Pediatric Hematology/Oncology, co-director of the GESR, and a member of the Stem Cell Institute at the University of Minnesota Medical School, where he is also a faculty member in the Department of Pediatrics, the Molecular Pharmacology & Therapeutics Graduate Program, and the Masters Program in Stem Cell Biology. He is also a member of the Masonic Cancer Center.

Latest:

CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

Denise M. Wolf, PhD

Latest:

Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast Cancer

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.

Madappa Kundranda, MD,PhD

Latest:

Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

Adrienne A. Boire, MD, PhD

Latest:

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

Chris Danes, Scientific Director, US Medical Affairs for Lung Cancer, Takeda Oncology

Latest:

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

Jeff Michalski, MD, MBA, FASTRO

Latest:

Dr. Michalski on the Goals ASTRO in Radiation Oncology

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.